Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lobe SciencesLOBEF +3.02% 3-Year EBITDA Growth Rate is 54.20% as of May. 2026, which is 159% above its 10-year median of 20.95. The stock has 2 warning signs investors should review. Among 1,127 Biotechnology companies, Lobe Sciences ranks better than 88.2% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 54.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 38.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 6.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Lobe Sciences was 54.20% per year. The lowest was -88.80% per year. And the median was 20.95% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Lobe Sciences 3-Year EBITDA Growth Rate Related Terms
LOBEF vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Lobe Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lobe Sciences 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lobe Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Lobe Sciences's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 54.20% mean?
Lobe Sciences (LOBEF) has a 3-Year EBITDA Growth Rate of 54.20% as of May. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Lobe Sciences and its competitors. This is 159% above median its historical median of 20.95. According to the industry distribution chart, Lobe Sciences ranks #133 out of 1127 companies in the Biotechnology industry, placing it in the top 11.8%.
Is Lobe Sciences' 3-Year EBITDA Growth Rate too high?
Lobe Sciences' current 3-Year EBITDA Growth Rate of 54.20% is 159% above median its 10-year median of 20.95. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Lobe Sciences' value of 54.20% is 271.2% above this industry median. Based on the distribution chart, Lobe Sciences ranks #133 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Lobe Sciences' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lobe Sciences ranks #133 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Lobe Sciences in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.60. Lobe Sciences' value of 54.20% is 271.2% above this benchmark. While the company's 10-year median is 20.95 vs. the industry median of 14.60, Lobe Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lobe Sciences's current 3-Year EBITDA Growth Rate of 54.20% is 271.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Lobe Sciences and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lobe Sciences's current 3-Year EBITDA Growth Rate is 54.20%, which is 159% above median its own 10-year median of 20.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lobe Sciences stock overvalued right now?
Lobe Sciences (LOBEF) has a current 3-Year EBITDA Growth Rate of 54.20%. The current 3-Year EBITDA Growth Rate is 54.20%, which is 159% above median its 10-year median of 20.95 and 271.2% above the Biotechnology industry median of 14.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Lobe Sciences (LOBEF), the current 3-Year EBITDA Growth Rate is 54.20% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lobe Sciences Ltd is a biopharmaceutical company focused on using lipid technology that develop therapies for orphan and rare diseases. It commercializes Altemia MF, a medical food intended to address nutritional deficiencies associated with sickle cell disease. Through its subsidiaries, the company also holds a majority interest in the development of Conjugated Psilocin for potential use in neurological and psychiatric indications. The company operates in one reportable segment, being the biopharmaceutical development of new medicines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LOBEF has been successfully added to your 
